ArticleParticle and fibre toxicology2016
Mesothelioma response to carbon nanotubes is associated with an early and selective accumulation of immunosuppressive monocytic cells.
Article in Particle and fibre toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 60 citations in OpenAlex.
- Impact of carbon-based fibers morphologies on their carcinogenic potential.Particle and fibre toxicology · 2026Article
- Critical values for dimensional parameters of mesotheliomagenic mineral fibers: evidence from the dimensions and rigidity of MWCNT.Frontiers in toxicology · 2025Article
- A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy Volunteers.Nanomaterials (Basel, Switzerland) · 2024Article
- Time-Course of Transcriptomic Change in the Lungs of F344 Rats Repeatedly Exposed to a Multiwalled Carbon Nanotube in a 2-Year Test.Nanomaterials (Basel, Switzerland) · 2023Article
- Myeloid-derived suppressor cells and pulmonary hypertension.Frontiers in immunology · 2023Review
- Grouping MWCNTs based on their similar potential to cause pulmonary hazard after inhalation: a case-study.Particle and fibre toxicology · 2022Article
- Single-cell transcriptomics reveals immune dysregulation mediated by IL-17A in initiation of chronic lung injuries upon real-ambient particulate matter exposure.Particle and fibre toxicology · 2022Article
- Two-year intermittent exposure of a multiwalled carbon nanotube by intratracheal instillation induces lung tumors and pleural mesotheliomas in F344 rats.Particle and fibre toxicology · 2022Article
- Do Carbon Nanotubes and Asbestos Fibers Exhibit Common Toxicity Mechanisms?Nanomaterials (Basel, Switzerland) · 2022Review
- Histological sequence of the development of rat mesothelioma by MWCNT, with the involvement of apolipoproteins.Cancer science · 2021Article
- Review
- Monocytic Ontogeny of Regenerated Macrophages Characterizes the Mesotheliomagenic Responses to Carbon Nanotubes.Frontiers in immunology · 2021Article
- Editorial: Immune Mechanisms in the Pathologic Response to Particles, Fibers, and Nanomaterials.Frontiers in immunology · 2021Article
- Carbon Nanotubes: A Summary of Beneficial and Dangerous Aspects of an Increasingly Popular Group of Nanomaterials.Frontiers in oncology · 2021Review
- Polarization of Immune Cells in the Pathologic Response to Inhaled Particulates.Frontiers in immunology · 2020Review
- Integration of inflammation, fibrosis, and cancer induced by carbon nanotubes.Nanotoxicology · 2019Review
- Toxicity of Carbon Nanotubes as Anti-Tumor Drug Carriers.International journal of nanomedicine · 2019Review
- Advances in Carbon Nanotubes for Malignant Melanoma: A Chance for Treatment.Molecular diagnosis & therapy · 2018Review
- Role of p53 in the chronic pulmonary immune response to tangled or rod-like multi-walled carbon nanotubes.Nanotoxicology · 2018Article
- P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes.ACS applied materials & interfaces · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe asbestos-like toxicity of some engineered carbon nanotubes (CNT), notably their capacity to induce mesothelioma, is a serious cause of concern for public health. Here we show that carcinogenic CNT induce an early and sustained immunosuppressive response characterized by the accumulation of monocytic Myeloid Derived Suppressor Cells (M-MDSC) that counteract effective immune surveillance of tumor cells.
methodsWistar rats and C57BL/6 mice were intraperitoneally injected with carcinogenic multi-walled Mitsui-7 CNT (CNT-7) or crocidolite asbestos. Peritoneal mesothelioma development and immune cell accumulation were assessed until 12 months. Leukocyte sub-populations were identified by recording expression of CD11b/c and His48 by flow cytometry. The immunosuppressive activity on T lymphocytes of purified peritoneal leukocytes was assessed in a co-culture assay with activated spleen cells.
resultsWe demonstrate that long and short mesotheliomagenic CNT-7 injected in the peritoneal cavity of rats induced, like asbestos, an early and selective accumulation of monocytic cells (CD11b/c(int) and His48(hi)) which possess the ability to suppress polyclonal activation of T lymphocytes and correspond to M-MDSC. Peritoneal M-MDSC persisted during the development of peritoneal mesothelioma in CNT-7-treated rats but were only transiently recruited after non-carcinogenic CNT (CNT-M, CNT-T) injection. Peritoneal M-MDSC did not accumulate in mice which are resistant to mesothelioma development.
conclusionsOur data provide new insights into the initial pathogenic events induced by CNT, adding a new component to the adverse outcome pathway leading to mesothelioma development. The specificity of the M-MDSC response after carcinogenic CNT exposure highlights the interest of this response for detecting the ability of new nanomaterials to cause cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.